Semaglutide vs Tirzepatide: How They Compare

What each drug is

Semaglutide is the active molecule in two brand-name products: Ozempic (FDA-approved for type 2 diabetes, 2017) and Wegovy (FDA-approved for chronic weight management, 2021). Both are once-weekly subcutaneous injections made by Novo Nordisk 1Ref 1Aronne LJ et al. (2025).Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.SURMOUNT-5 head-to-head RCT: tirzepatide −20.2% vs semaglutide −13.7% body weight at 72 weeks; GI discontinuation rates 2.7% vs 5.6%; waist circumference reduction 18.4 cm vs 13.0 cm.

Tirzepatide is the active molecule in Mounjaro (FDA-approved for type 2 diabetes, 2022) and Zepbound (FDA-approved for chronic weight management, November 2023). Both are once-weekly injections made by Eli Lilly 2Ref 2Jastreboff AM et al. (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 trial: tirzepatide 15 mg achieved 22.5% weight loss vs 2.4% placebo over 72 weeks; FDA approval basis for Zepbound (tirzepatide) for chronic weight management.

For people whose primary goal is weight loss, Wegovy and Zepbound are the on-label products. Ozempic and Mounjaro are approved for diabetes and are sometimes prescribed off-label for weight loss, though insurance coverage for that use is less consistent.

The brand-name maze matters for insurance: a plan that covers Mounjaro for diabetes may not cover Zepbound for weight loss, even though they contain the same drug.

How they work — one receptor versus two

The core mechanistic difference is how many hormonal pathways each drug activates.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is released by the gut after meals. Semaglutide mimics it with high potency, signaling the pancreas to release insulin in a glucose-dependent way, suppressing glucagon (which raises blood sugar), slowing gastric emptying so food stays in the stomach longer, and acting on appetite centers in the brain to reduce hunger 3Ref 3Liu QK (2024).Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.Mechanistic distinction: semaglutide as GLP-1R agonist (EC50 6.2 pM); tirzepatide as imbalanced dual GIP/GLP-1 agonist with biased GLP-1R signaling favoring cAMP over beta-arrestin.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind. In addition to GLP-1R activation, it activates receptors for GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone. Tirzepatide acts as an imbalanced agonist: its GIPR affinity is equivalent to native GIP, while its GLP-1R potency is intentionally weaker, producing a biased signaling pattern that appears to amplify fat-cell metabolism through both pathways simultaneously 3Ref 3Liu QK (2024).Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.Mechanistic distinction: semaglutide as GLP-1R agonist (EC50 6.2 pM); tirzepatide as imbalanced dual GIP/GLP-1 agonist with biased GLP-1R signaling favoring cAMP over beta-arrestin.

Researchers believe the synergy between GIP and GLP-1 receptor activation explains tirzepatide's larger weight-loss effect, though the precise mechanism is still under study.

What the trials show

STEP 1 (semaglutide): A 68-week randomized controlled trial in 1,961 adults with obesity or overweight found that semaglutide 2.4 mg/week produced a mean body-weight reduction of 14.9% versus 2.4% for placebo. 86% of participants on semaglutide achieved at least 5% weight loss 6Ref 6Wilding JPH et al. (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: semaglutide 2.4 mg/week produced 14.9% mean body-weight reduction vs 2.4% placebo over 68 weeks in 1,961 adults with obesity; 86% achieved ≥5% weight loss.

SURMOUNT-1 (tirzepatide): A 72-week RCT found that tirzepatide at 5, 10, and 15 mg/week produced 16.0%, 21.4%, and 22.5% weight loss, respectively, versus 2.4% for placebo 2Ref 2Jastreboff AM et al. (2022).Tirzepatide Once Weekly for the Treatment of Obesity.SURMOUNT-1 trial: tirzepatide 15 mg achieved 22.5% weight loss vs 2.4% placebo over 72 weeks; FDA approval basis for Zepbound (tirzepatide) for chronic weight management.

SURMOUNT-5 (head-to-head): Published in the New England Journal of Medicine in July 2025, this is the direct comparison both drugs' users have waited for. In 751 adults with obesity (no diabetes) treated for 72 weeks at maximum tolerated doses:

| | Tirzepatide | Semaglutide | |---|---|---| | Mean weight change | −20.2% | −13.7% | | Waist circumference | −18.4 cm | −13.0 cm | | Achieved ≥30% weight loss | 19.7% | 6.9% | | Discontinued for GI events | 2.7% | 5.6% |

The difference was statistically significant (p<0.001) 1Ref 1Aronne LJ et al. (2025).Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.SURMOUNT-5 head-to-head RCT: tirzepatide −20.2% vs semaglutide −13.7% body weight at 72 weeks; GI discontinuation rates 2.7% vs 5.6%; waist circumference reduction 18.4 cm vs 13.0 cm.

A 2026 real-world cohort study (n=not disclosed, 6-month follow-up in US clinical practice) confirmed the direction: tirzepatide users lost 11.15% of body weight versus 8.83% for semaglutide, with tirzepatide outperforming on every weight-loss threshold tested 5Ref 5le Roux CW, Done N, Brnabic AJM et al. (2026).Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.Real-world 6-month comparison: tirzepatide −11.15% vs semaglutide −8.83% body weight; tirzepatide superior on all weight-loss thresholds (≥5%, ≥10%, ≥15%, ≥20%) and cardiometabolic markers.

The SURMOUNT-5 result was the first rigorous head-to-head comparison. Prior indirect comparisons across separate trials were complicated by different populations, follow-up lengths, and dose titration schedules.

FDA approvals and cardiovascular indications

Semaglutide (Wegovy) earned an additional FDA indication in March 2024: reducing the risk of major adverse cardiovascular events (MACE — cardiovascular death, nonfatal heart attack, nonfatal stroke) in adults with established cardiovascular disease and obesity or overweight. This was based on the SELECT trial, a 17,604-person RCT that found semaglutide reduced MACE risk by 20% versus placebo over a mean follow-up of nearly 40 months 4Ref 4Lincoff AM et al. (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced MACE risk 20% vs placebo over 39.8 months in 17,604 adults with CVD and obesity (no diabetes); basis for March 2024 FDA cardiovascular indication for Wegovy.

Tirzepatide (Zepbound) does not yet have a cardiovascular outcomes indication. Cardiovascular outcome trials for tirzepatide are ongoing.

For patients with established heart disease, the cardiovascular data for semaglutide are a meaningful differentiator as of mid-2026.

Side effects and safety

Both drugs share a side-effect profile dominated by gastrointestinal effects, because slowing gastric emptying is central to how they work.

Common (both drugs): - Nausea (most common, especially during dose escalation) - Vomiting - Diarrhea - Constipation - Abdominal pain or discomfort - Decreased appetite

GI effects are usually mild to moderate and occur primarily during the ramp-up phase. Slower dose titration consistently improves tolerability for both drugs [1, 2].

In SURMOUNT-5, GI-related discontinuations were higher with semaglutide (5.6%) than tirzepatide (2.7%), suggesting tirzepatide may be somewhat better tolerated at maximum doses in direct comparison.

Serious risks (both drugs — FDA Boxed Warning):

Both semaglutide and tirzepatide carry a Boxed Warning for thyroid C-cell tumors. In rodent studies, both drugs caused thyroid tumors including medullary thyroid carcinoma (MTC). Whether this risk applies to humans is not known. Both drugs are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1, 2].

Other serious risks (both drugs): pancreatitis, gallbladder disease (including gallstones), acute kidney injury (often from dehydration during GI illness), increased heart rate.

Diabetic retinopathy worsening has been observed with rapid glycemic improvement on semaglutide; patients with pre-existing retinopathy should be monitored 1Ref 1Aronne LJ et al. (2025).Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.SURMOUNT-5 head-to-head RCT: tirzepatide −20.2% vs semaglutide −13.7% body weight at 72 weeks; GI discontinuation rates 2.7% vs 5.6%; waist circumference reduction 18.4 cm vs 13.0 cm.

Neither drug is recommended during pregnancy.

Cost and access

Cost is a major practical factor. As of mid-2026, list prices for the single-use pen injectors are approximately:

| | Wegovy (semaglutide) | Zepbound (tirzepatide) | |---|---|---| | List price (pen) | ~$1,349/month | ~$1,086/month | | Manufacturer cash price (vial) | ~$349–$399/month | ~$299–$449/month |

Eli Lilly cut Zepbound vial cash prices significantly in late 2025. Novo Nordisk introduced a similar manufacturer program for Wegovy. Cash prices via vial form are meaningfully lower than pen list prices, though vials require separate needles and correct storage.

Insurance: Coverage for weight-loss indications remains inconsistent across commercial plans. Many plans cover Mounjaro or Ozempic for diabetes but exclude Zepbound or Wegovy for weight loss. Prior authorization requirements are common for both, typically requiring BMI documentation and sometimes evidence of a supervised diet-and-exercise program.

Medicare: Medicare Part D covers Wegovy for patients with established cardiovascular disease under the SELECT indication. Coverage of Zepbound for weight loss under Medicare Part D is pending policy decisions as of mid-2026.

Patient assistance: Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares) operate assistance programs for patients below certain income thresholds. Manufacturer savings cards can substantially reduce out-of-pocket costs for commercially insured patients (but do not apply to Medicare or Medicaid).

Who each drug may be preferred for

This is a clinical decision that belongs to a prescriber who knows the individual patient. Factors that clinicians weigh include:

• Established cardiovascular disease: Wegovy (semaglutide) has the cardiovascular outcomes data and the FDA label for MACE risk reduction; tirzepatide does not yet.
• Maximizing weight loss: SURMOUNT-5 shows tirzepatide produces meaningfully greater average weight loss at maximum tolerated doses.
• GI tolerability history: In the head-to-head trial, tirzepatide had a lower GI discontinuation rate.
• Insurance and cost: Some plans cover one and not the other. This often drives the clinical decision.
• Contraindications: Both drugs are contraindicated in MTC/MEN 2 history. This applies equally to both.
• Diabetes: For patients with type 2 diabetes, Ozempic and Mounjaro are the diabetes-indicated forms. Tirzepatide showed consistently superior HbA1c reduction in SURPASS trials.

Individual response varies: some patients who respond poorly to one agent do better on the other, even when the average group data favor one drug.